Tirzepatide is a different animal than most of the compounds discussed on this site, because it already cleared the FDA. That single fact splits its access story into three separate lanes, and conflating them is where most confusion about "how to get tirzepatide" starts. This guide separates the three, explains what changed in the compounding channel, and focuses in depth on the lane that has no pharmacy gatekeeper at all: the research-compound market.
It is written for research and educational purposes. It describes how each market works and does not instruct anyone to self-administer. For the full clinical picture of what tirzepatide is and what its trials showed, see the complete tirzepatide guide.
The three ways to get tirzepatide in 2026
| Route | What it is | Prescription required | Status in 2026 |
|---|---|---|---|
| Branded prescription (Mounjaro, Zepbound) | FDA-approved tirzepatide manufactured by Eli Lilly | Yes | Available; list price above $1,000 a month without insurance |
| Compounding pharmacy | Non-branded copies made under a shortage-based exception | Yes | Mostly closed since the FDA's December 2024 order resolved the shortage [1] |
| Research-compound market | Peptide supplied for laboratory and pre-clinical study | No | The route this guide covers in depth |
The table is the whole story in outline. What follows fills in why each row looks the way it does, and, for the row without a pharmacy gatekeeper, what actually separates a trustworthy source from a risky one.
The prescription route: Mounjaro and Zepbound
Tirzepatide's dual GLP-1/GIP mechanism was studied in the SURMOUNT program for weight management and the SURPASS program for type 2 diabetes, and it is the only compound on this site with a completed Phase 3 program and regulatory approval behind it. In its pivotal obesity trial, the 15 mg dose produced 20.9% mean body-weight loss at 72 weeks. [2] That evidence base is why a doctor can prescribe it and a pharmacy can dispense it: Mounjaro for type 2 diabetes, Zepbound for chronic weight management, both FDA approved.
The friction in this lane is not legality, it is cost and access. List price without insurance commonly runs above $1,000 a month, and coverage depends heavily on the specific plan and the indication: diabetes coverage for Mounjaro tends to be broader than obesity coverage for Zepbound, since many insurers still treat obesity medications as a separate, more restricted benefit category. Manufacturer savings cards can lower the price for insured and some uninsured patients, but eligibility and the discount amount change frequently. None of that is a workaround this guide can offer; it is a question for a prescribing clinician and a specific insurance plan.
What happened to compounded tirzepatide
For much of 2023 and 2024, tirzepatide appeared on the FDA's drug shortage list, and that shortage created a legal basis for state-licensed 503A pharmacies and 503B outsourcing facilities to compound non-branded versions. During that window, compounded tirzepatide was commonly priced at a few hundred dollars a month, a fraction of branded list price, and it became a major access route for people who were priced out of Mounjaro or Zepbound.
That changed on December 19, 2024, when the FDA issued a declaratory order determining that the tirzepatide shortage was resolved. [1] The order followed an earlier October 2024 resolution determination, a legal challenge from an outsourcing-facility trade group, and a re-confirmation after remand. Once the shortage was formally resolved, the exception that had permitted broad compounding no longer applied. State-licensed 503A pharmacies were given until February 18, 2025 to stop, and 503B outsourcing facilities until March 19, 2025, aside from narrow exceptions tied to documented, patient-specific clinical need such as an allergy to an inactive ingredient in the branded product.
Practically, that means the compounding lane that many "tirzepatide compound" and "tirzepatide compounding pharmacy" searches are still pointed at has narrowed to a fraction of its former footprint. A pharmacy still openly compounding tirzepatide at scale in 2026, outside a documented patient-specific exception, is operating outside the position the FDA has staked out, which is itself a red flag worth knowing about before you engage with one.
The research-compound market: what "research use only" means
With the compounding lane mostly closed, the market that has no pharmacy gatekeeper at all is the research-compound market: tirzepatide peptide supplied "for research use only," intended for laboratory and pre-clinical study, not for human administration. This is a real regulatory category, not a euphemism. It describes what the product is and how it is labeled and sold, and it is worth being precise about because the phrase is widely misread as a wink-and-nod workaround. It is not that. It is an accurate description of the product's intended use.
Because there is no pharmacy standing between a manufacturer and the buyer, no one is checking each batch on the buyer's behalf. That puts the entire burden of quality verification on the buyer's ability to evaluate a supplier, which is the skill this guide is really about.
How to evaluate a research-compound source: the checklist
| Requirement | What good looks like |
|---|---|
| Certificate of analysis | Tied to a specific lot number, not a generic catalog spec sheet |
| Identity | Confirmed by mass spectrometry |
| Purity | Measured by HPLC, reported as a number, not a claim |
| Impurity profile | The non-target fraction is characterized, not unknown |
| Independent testing | Verified by a third-party lab, not only the manufacturer's own |
| Transparency | The supplier volunteers this documentation rather than dodging it |
The single most important item is the batch-matched COA verified by an independent lab. A manufacturer's own certificate is a starting point, not proof, since self-reported figures cannot be audited on their own. A supplier who sends a sample out for independent re-testing and shows you the result is demonstrating the one thing you cannot verify yourself from a listing page.
The two measurements that matter most on that document are identity, confirmed by mass spectrometry, and purity with a characterized impurity profile, measured by HPLC. Purity determination by chromatography is a standardized method. [3] The reason the impurity fraction needs to be identified, not just quantified, is the whole basis of impurity-qualification guidance: an unknown 1% carries a different risk than a known one. [4]
Red flags to walk away from
- No lot-specific COA: a generic spec sheet or a purity claim with no document behind it.
- A purity number with no impurity profile. "99% pure" means little if no one can say what the other 1% is.
- Only the manufacturer's own testing, with no independent verification offered.
- A price far below every other listing. Independent testing across lots costs money, and a rock-bottom price often means that step was skipped.
- A pharmacy or storefront still marketing compounded tirzepatide at scale in 2026 with no documented patient-specific exception, given where the FDA's order left that channel. [1]
- Evasiveness. A source reluctant to produce documentation is telling you something.
Questions to ask a supplier before ordering
A short, direct list separates transparent suppliers from evasive ones. A legitimate source answers all of these without friction:
- Can I see the COA for the specific lot I would receive, not a representative or generic one?
- Was identity confirmed by mass spectrometry and purity by HPLC?
- Is the impurity profile characterized, and what is in it?
- Was this verified by an independent lab, or only your own?
- Do you test every lot, or only occasionally?
The answers matter less than the willingness to give them. A supplier who treats these as reasonable questions is showing you their process; one who deflects is showing you something too.
What you actually receive
Research-grade tirzepatide is supplied as a lyophilized, freeze-dried powder, since dry peptide is far more stable than peptide already in solution. It has to be reconstituted with bacteriostatic water before any laboratory use: added gently, swirled rather than shaken, and stored refrigerated with the date labeled. The full procedure is in how to reconstitute peptides with bacteriostatic water. The point for a buyer is straightforward: a well-sourced vial only stays well-characterized if it is handled correctly once it arrives, so plan for the supplies and the technique, not just the compound itself.
Cost across the three lanes
| Route | Typical monthly cost | What drives the price |
|---|---|---|
| Branded prescription (list price) | $1,000 or more without insurance | Manufacturer pricing; savings cards can reduce this for eligible patients |
| Branded prescription (insured) | Ranges widely, sometimes near copay-only | Plan design; diabetes coverage for Mounjaro is typically broader than obesity coverage for Zepbound |
| Compounding pharmacy (where it still legally applies) | Was commonly a few hundred dollars during the shortage | Narrower compounding now applies mainly to documented, patient-specific exceptions [1] |
| Research-compound market | Varies by vendor, purity, and independent testing depth | Rigorous third-party testing costs more; the cheapest listing usually means that cost was cut |
The pattern worth internalizing, especially for the "cheapest tirzepatide" searches: in every lane, the gap between a rigorously verified product and a bargain one is largely the cost of the verification itself. Paying for independent testing is paying to actually know what is in the vial, which for a research compound is the entire point of buying carefully.
Is it legal to buy tirzepatide
Branded tirzepatide is a legal prescription medication, full stop, when it is dispensed by a licensed pharmacy against a valid prescription. Compounded tirzepatide is legal only within the narrowed exceptions that remain after the shortage was declared resolved. [1] Research-grade tirzepatide is sold under the "research use only" category described above: real, regulated, and explicitly not sold or labeled for human administration. This guide describes how each of those three markets works. It is not medical advice, and it does not advise anyone to self-administer a research compound.
Frequently asked questions
- How do you get tirzepatide in the US?
- There are three routes. Branded tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is FDA approved and available by prescription. A compounding-pharmacy channel existed during the national shortage but narrowed sharply after the FDA's December 2024 order resolved it. Research-grade tirzepatide is also available through the research-compound market for laboratory and pre-clinical study, sourced independent of a pharmacy.
- Is tirzepatide legal to buy?
- Branded tirzepatide is a legal prescription medication when dispensed through a licensed pharmacy against a valid prescription. Research-grade tirzepatide is sold "for research use only," a real regulatory category describing laboratory-use material, not a workaround for personal use. This guide describes how each market works; it is not medical advice and does not instruct anyone to self-administer.
- Can I still get tirzepatide from a compounding pharmacy?
- Mostly no. The FDA determined the tirzepatide shortage was resolved on December 19, 2024, which removed the shortage-based legal basis compounders had relied on. State-licensed 503A pharmacies had until February 18, 2025 and outsourcing facilities (503B) until March 19, 2025 to stop compounding copies, aside from narrow patient-specific exceptions.
- What does "research use only" mean for tirzepatide?
- It means the material is supplied for laboratory and in-vitro study and is explicitly not intended, tested, or approved for human use in that form. It is a description of the product and its regulation, not a legal loophole for personal use.
- How do I know a research-grade tirzepatide source is legitimate?
- Require a batch-matched certificate of analysis tied to a specific lot (identity by mass spectrometry, purity by HPLC as a measured number, and a characterized impurity profile), ideally verified by an independent third-party lab rather than only the manufacturer's own testing.
Glossary
- 503A pharmacy
- A state-licensed compounding pharmacy that can prepare patient-specific medications under narrower rules than an outsourcing facility.
- 503B outsourcing facility
- A compounding facility registered with the FDA that can produce larger batches, subject to its own set of federal requirements.
- Drug shortage declaratory order
- A formal FDA determination of whether a drug's shortage status is ongoing or resolved, which governs what compounders may legally produce.
- Research use only (RUO)
- Material supplied for laboratory or in-vitro study, explicitly not intended, tested, or approved for human use.
- Certificate of analysis (COA)
- A lab document reporting the measured identity and purity of a specific production lot.
- HPLC
- High-performance liquid chromatography: separates and quantifies a compound and its impurities to measure purity.
References
- U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (December 19, 2024).
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- United States Pharmacopeia (USP). General Chapter <621> Chromatography: HPLC purity determination methods.
- ICH Q3A(R2). Impurities in New Drug Substances: guideline on characterizing and qualifying impurities.
For research and educational purposes only. Not medical advice. This guide describes how the branded prescription market, the compounding-pharmacy market, and the research-compound market work, and how to evaluate a research-compound supplier; it does not instruct anyone to self-administer. Research-grade tirzepatide is sold for laboratory and pre-clinical study and is not approved for human use in that form.